New Drug Approvals Archive
Fosamax Plus D (alendronate and cholecalciferol) Tablets
Date of Approval: April 7, 2005
Fosamax Plus D is a single once-weekly tablet containing the bisphosphonate drug alendronate, and seven days’ worth of vitamin D, an essential nutrient required for calcium absorption. Fosamax Plus D is used to reduce the risk of hip and spinal fractures in postmenopausal women with osteoporosis, and to increase bone mass in men with osteoporosis.
Retisert (fluocinolone acetonide) Intravitreal Implant
Date of Approval: April 8, 2005
Retisert (fluocinolone acetonide) intravitreal implant is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
Byetta (exenatide) Injection
Date of Approval: April 28, 2005
Byetta (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
New Indication Approved: November 2, 2009
New Dosage Regimen: October 19, 2011